LIPOSYN 10%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIPOSYN 10% (LIPOSYN 10%).
Intravenous fat emulsion provides a source of calories and essential fatty acids as a component of parenteral nutrition. The lipid particles are metabolized similarly to endogenous chylomicrons, undergoing hydrolysis by lipoprotein lipase to release free fatty acids, which are then used for energy or stored.
| Metabolism | Lipoprotein lipase hydrolyzes triglycerides to free fatty acids and glycerol. Free fatty acids are metabolized via beta-oxidation in tissues or re-esterified. Clearance is dependent on lipase activity. |
| Excretion | Renal: negligible; biliary: negligible; fecal: negligible; eliminated via peripheral lipoprotein lipase-mediated hydrolysis and subsequent metabolism of fatty acids, with CO2 production (~50-60%) and recycling into triglycerides and phospholipids; complete clearance from plasma within 24 hours of infusion cessation. |
| Half-life | Lipid emulsion particles: elimination half-life of 10-15 minutes; triglycerides: terminal half-life of 1-3 hours, reflecting redistribution and clearance from adipose tissue; clinical context: half-life is dose-dependent and prolonged in hypertriglyceridemia, hepatic impairment, or sepsis. |
| Protein binding | Free fatty acids bound to albumin (>99%); phospholipids and triglycerides bound to lipoproteins (VLDL, HDL); no binding of parent lipid emulsion particles. |
| Volume of Distribution | Initial Vd of lipid particles approximately 0.06 L/kg (limited to plasma compartment); apparent Vd for triglycerides: 0.1-0.2 L/kg, indicating distribution into extracellular fluid and peripheral tissues (adipose, muscle); clinical meaning: low Vd reflects confinement to vascular space initially, with gradual tissue uptake. |
| Bioavailability | Intravenous: 100% bioavailable; not administered via other routes; oral bioavailability: 0% (not absorbable due to large particle size and lipolysis in GI tract; used exclusively as IV infusion). |
| Onset of Action | Intravenous: immediate rise in plasma free fatty acids within 5-10 minutes; calorimetric effects (increase in oxygen consumption) within 1-2 hours; therapeutic effects on essential fatty acid deficiency (EFAD) reversal noted within 2-4 weeks of regular administration. |
| Duration of Action | Intravenous: metabolic effects persist for 8-12 hours post-infusion; EFAD correction requires continuous administration; single infusion does not sustain plasma fatty acid levels beyond 24 hours; clinical notes: duration depends on infusion rate and patient's lipid clearance capacity. |
Intravenous infusion: 1-2 g/kg/day (10-20 mL/kg/day) as part of parenteral nutrition, not to exceed 2.5 g/kg/day. Infusion rate: initially 0.5-1 mL/min for 30 minutes, then increase to maximum 125 mL/hour if tolerated.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; monitor serum triglycerides and electrolytes closely in renal impairment. |
| Liver impairment | Contraindicated in severe hepatic insufficiency (Child-Pugh class C); use with caution in mild-moderate impairment; reduce dose by 50% if triglycerides exceed 400 mg/dL. |
| Pediatric use | Infants and children: Initial 1 g/kg/day IV, increase by 0.5-1 g/kg/day to maximum 3 g/kg/day; infusion rate not to exceed 0.17 g/kg/hour. |
| Geriatric use | Start at low end of dosing range; monitor triglyceride levels and renal function; consider dose reduction due to decreased clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIPOSYN 10% (LIPOSYN 10%).
| Breastfeeding | Intravenous fat emulsion is considered compatible with breastfeeding. No M/P ratio available; small amounts of lipid emulsions are expected to be excreted in breast milk but not likely to cause harm to the infant. |
| Teratogenic Risk | Liposyn 10% (intravenous fat emulsion) is not known to be teratogenic. No fetal harm has been reported in animal studies or human case series. Use in pregnancy only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
Deaths in preterm infants have been reported with use of intravenous fat emulsions. Use in preterm and low-birth-weight infants should be carefully monitored due to risk of fat overload syndrome and pulmonary lipid accumulation. Contains soybean oil and egg phospholipids; use is contraindicated in patients with hypersensitivity to these components.
| Serious Effects |
["Hypersensitivity to eggs, soybean, or peanuts","Severe hyperlipidemia","Severe coagulopathy","Kernicterus (risk of bilirubin displacement)","Fat embolism or acute fat metabolism disorders"]
| Precautions | ["Risk of fat overload syndrome (hypertriglyceridemia, hepatomegaly, coagulopathy, and organ dysfunction) with rapid infusion or in patients with impaired lipid metabolism","Monitor serum triglycerides, liver function, and platelet count","Increased risk of infections due to lipid emulsions supporting microbial growth; use strict aseptic technique","Use caution in patients with severe hepatic impairment, pancreatitis, or hyperlipidemia","Not for use in patients with egg, soybean, or peanut allergy"] |
Loading safety data…
| Monitor maternal serum triglycerides and for signs of fat overload syndrome (e.g., hepatomegaly, coagulopathy, hypertriglyceridemia). Monitor fetal growth if prolonged use in second/third trimester. |
| Fertility Effects | No known effect on fertility. Limited data; no reproductive toxicity reported in animal studies. |